Long-term effect of risankizumab on improved and sustained health-related quality of life over 3 years in patients with moderate to severe Crohn's disease: interim analysis of a phase 2 open-label extension study

Edouard Louis  1     Peter Bossuyt  2     Julian Panés  3     Brian G. Feagan  4     Jasmina Kalabic  5     Kori Wallace  6     Naijun Chen  7     Wan-Ju Lee     Marc Ferrante    
1 University Hospital CHU of Liège,Liège,Belgium
2 Imelda Hospital,Bonheiden,Belgium
3 Hospital Clinic de Barcelona,Barcelona,Spain
4 Robarts Clinical Trials, University of Western Ontario,London,Canada
5 AbbVie Deutschland GmbH & Co. KG,Ludwigshafen,Germany
6 AbbVie Inc.,North Chicago,United States
7 AbbVie Inc.,North Chicago,United Sta

IBD I (Posters)

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing